Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease

Dateline City:

KENILWORTH, N.J.

APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimer’s Ongoing

KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the company’s investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimer’s disease (AD). The ongoing study commenced in November 2012, completed enrollment in the fourth quarter of 2015 and is estimated to reach primary trial completion in July 2017.
Language:

English

read more

Source: Merck.com - Research and Development News - January 28, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news